Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Bacterial Infections and Mycoses

ClinicalTrials.gov lists 7,535 trials for Bacterial Infections and Mycoses or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 356.

MeSH D001423 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 810 Phase 1/2 Phase 1/2 174 Phase 2 Phase 2 1,028 Phase 2/3 Phase 2/3 142 Phase 3 Phase 3 1,146 Phase 4 Phase 4 750 Not applicable Not applicable 1,429 Observational Observational 2,041 Phase 1 Phase 1 810 Phase 1/2 Phase 1/2 174 Phase 2 Phase 2 1,028 Phase 2/3 Phase 2/3 142 Phase 3 Phase 3 1,146 Phase 4 Phase 4 750 Not applicable Not applicable 1,429 Observational Observational 2,041

Trials per phase

2 more sections with rows

16 of the 7,535 trials are tagged with Bacterial Infections and Mycoses itself; the rest are tagged with a narrower condition beneath it.

Get the Bacterial Infections and Mycoses report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Bacterial Infections and Mycoses trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 17 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 429

1990: 1 trials (Phase 2 1) 1991: 6 trials (Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 3) 1992: 3 trials (Observational 1, Phase 3 1, Phase 2 1) 1993: 5 trials (Observational 1, Phase 3 3, Phase 2 1) 1994: 8 trials (Observational 2, Not applicable 1, Phase 4 4, Phase 2 1) 1995: 14 trials (Observational 8, Not applicable 1, Phase 3 3, Phase 2 1, Phase 1 1) 1996: 4 trials (Observational 1, Phase 4 2, Phase 2 1) 1997: 16 trials (Observational 3, Not applicable 1, Phase 4 2, Phase 3 8, Phase 2 1, Phase 1 1) 1998: 13 trials (Observational 4, Not applicable 1, Phase 3 4, Phase 2 2, Phase 1 2) 1999: 27 trials (Observational 4, Not applicable 2, Phase 3 10, Phase 2/3 1, Phase 2 9, Phase 1 1) 2000: 32 trials (Observational 7, Not applicable 7, Phase 4 2, Phase 3 9, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2001: 35 trials (Observational 6, Not applicable 1, Phase 4 9, Phase 3 11, Phase 2/3 1, Phase 2 6, Phase 1 1) 2002: 65 trials (Observational 11, Not applicable 5, Phase 4 10, Phase 3 20, Phase 2/3 2, Phase 2 9, Phase 1/2 2, Phase 1 6) 2003: 93 trials (Observational 11, Not applicable 9, Phase 4 17, Phase 3 24, Phase 2/3 2, Phase 2 20, Phase 1/2 2, Phase 1 8) 2004: 125 trials (Observational 19, Not applicable 14, Phase 4 19, Phase 3 35, Phase 2/3 4, Phase 2 18, Phase 1/2 6, Phase 1 10) 2005: 190 trials (Observational 51, Not applicable 17, Phase 4 17, Phase 3 49, Phase 2/3 3, Phase 2 32, Phase 1/2 1, Phase 1 20) 2006: 237 trials (Observational 53, Not applicable 22, Phase 4 32, Phase 3 76, Phase 2/3 2, Phase 2 32, Phase 1/2 5, Phase 1 15) 2007: 255 trials (Observational 48, Not applicable 32, Phase 4 38, Phase 3 65, Phase 2/3 4, Phase 2 32, Phase 1/2 4, Phase 1 32) 2008: 281 trials (Observational 64, Not applicable 26, Phase 4 42, Phase 3 62, Phase 2/3 2, Phase 2 46, Phase 1/2 7, Phase 1 32) 2009: 258 trials (Observational 63, Not applicable 44, Phase 4 18, Phase 3 46, Phase 2/3 7, Phase 2 40, Phase 1/2 6, Phase 1 34) 2010: 294 trials (Observational 63, Not applicable 35, Phase 4 35, Phase 3 50, Phase 2/3 5, Phase 2 62, Phase 1/2 8, Phase 1 36) 2011: 275 trials (Observational 72, Not applicable 37, Phase 4 32, Phase 3 56, Phase 2/3 3, Phase 2 45, Phase 1 30) 2012: 272 trials (Observational 74, Not applicable 38, Phase 4 40, Phase 3 45, Phase 2/3 9, Phase 2 29, Phase 1/2 5, Phase 1 32) 2013: 279 trials (Observational 62, Not applicable 52, Phase 4 29, Phase 3 43, Phase 2/3 5, Phase 2 37, Phase 1/2 9, Phase 1 42) 2014: 295 trials (Observational 71, Not applicable 49, Phase 4 34, Phase 3 52, Phase 2/3 11, Phase 2 45, Phase 1/2 6, Phase 1 27) 2015: 303 trials (Observational 83, Not applicable 70, Phase 4 28, Phase 3 33, Phase 2/3 4, Phase 2 42, Phase 1/2 6, Phase 1 37) 2016: 308 trials (Observational 88, Not applicable 56, Phase 4 35, Phase 3 31, Phase 2/3 4, Phase 2 46, Phase 1/2 5, Phase 1 43) 2017: 327 trials (Other 1, Observational 97, Not applicable 77, Phase 4 34, Phase 3 29, Phase 2/3 5, Phase 2 33, Phase 1/2 12, Phase 1 39) 2018: 330 trials (Observational 95, Not applicable 69, Phase 4 24, Phase 3 38, Phase 2/3 10, Phase 2 54, Phase 1/2 4, Phase 1 36) 2019: 429 trials (Observational 139, Not applicable 88, Phase 4 37, Phase 3 48, Phase 2/3 9, Phase 2 53, Phase 1/2 16, Phase 1 39) 2020: 331 trials (Observational 120, Not applicable 65, Phase 4 21, Phase 3 39, Phase 2/3 9, Phase 2 36, Phase 1/2 2, Phase 1 39) 2021: 394 trials (Observational 137, Not applicable 96, Phase 4 32, Phase 3 33, Phase 2/3 5, Phase 2 49, Phase 1/2 10, Phase 1 32) 2022: 367 trials (Other 1, Observational 116, Not applicable 71, Phase 4 32, Phase 3 40, Phase 2/3 6, Phase 2 48, Phase 1/2 12, Phase 1 41) 2023: 362 trials (Observational 110, Not applicable 93, Phase 4 30, Phase 3 34, Phase 2/3 6, Phase 2 36, Phase 1/2 10, Phase 1 43) 2024: 381 trials (Observational 122, Not applicable 98, Phase 4 22, Phase 3 39, Phase 2/3 8, Phase 2 40, Phase 1/2 17, Phase 1 35) 2025: 348 trials (Observational 119, Not applicable 73, Phase 4 31, Phase 3 35, Phase 2/3 9, Phase 2 36, Phase 1/2 7, Phase 1 38)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 352
2025 348
2024 381
2023 362
2022 367
2021 394
2020 331
2019 429
2018 330
2017 327

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 390 trials starting in 2026 and about 370 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 473 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 4,887 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Bacterial Infections and Mycoses trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 810
Phase 1/2 174
Phase 2 1,028
Phase 2/3 142
Phase 3 1,146
Phase 4 750
Not applicable 1,429
Observational 2,041
Expanded access 13
Unknown 2

How many Bacterial Infections and Mycoses trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 296
Recruiting 652
Enrolling by invitation 36
Active, not recruiting 191
Available 4

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Bacterial Infections and Mycoses trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
GlaxoSmithKline 356
National Institute of Allergy and Infectious Diseases (NIAID) 305
Pfizer 205
Sanofi Pasteur, a Sanofi Company 127
Merck Sharp & Dohme LLC 122

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Bacterial Infections and Mycoses? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Bedaquiline 61
Itraconazole 56

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Isoniazida 104
Fluconazol 101
Rifampicin 95
1% Azithromycin 93
Vancomycin 1.1% 91

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Bacterial Infections and Mycoses trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 3,332 375
Gastroenteritis 2,484 202
Preterm delivery 2,457 1
Small for gestational age 2,457 1
Bronchiolitis 2,295 127

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: publications, prevalence, and rare-disease identity.

Browse all condition evidence pages